Krystal Biotech saw the highest growth of 249% in patent filings and 49% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 249% and grants by 49%. GlobalData’s DataBook provides a comprehensive analysis of Krystal Biotech‘s patent filings and grants. Buy the databook here.
Krystal Biotech has been focused on protecting inventions in United States(US) with four publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 100% grants. The United States(US), Australia(AU), Chile(CL), and Israel(IL) patent Office are among the top ten patent offices where Krystal Biotech is filings its patents. Among the top granted patent authorities, Krystal Biotech has 100% of its grants in United States(US)
Amgen and Replimune Group could be the strongest competitors for Krystal Biotech
Patents related to genomics and rare diseases lead Krystal Biotech's portfolio
Krystal Biotech has the highest number of patents in genomics followed by, rare diseases. For genomics, nearly 50% of patents were filed and 100% of patents were granted in Q4 2023.
Lung cancer related patents lead Krystal Biotech portfolio followed by nonmelanomatous skin cancer, and secondary cns lymphoma
Krystal Biotech has highest number of patents in lung cancer followed by nonmelanomatous skin cancer, secondary cns lymphoma, non-small cell lung cancer, and extrahepatic bile duct cancer. For lung cancer, nearly 3% of patents were filed and 1% of patents were granted in Q4 2023.
For comprehensive analysis of Krystal Biotech's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.